BMY - BRISTOL MYERS SQUIBB CO
Close
57.665
-0.075 -0.130%
Share volume: 67,506
Last Updated: Fri 27 Dec 2024 02:30:01 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.34%
PREVIOUS CLOSE
CHG
CHG%
$57.74
-0.08
-0.13%
Fundamental analysis
40%
Profitability
23%
Dept financing
48%
Liquidity
71%
Performance
49%
Performance
5 Days
0.31%
1 Month
-1.67%
3 Months
15.24%
6 Months
35.91%
1 Year
12.26%
2 Year
-20.45%
Key data
Stock price
$57.66
DAY RANGE
$57.53 - $57.86
52 WEEK RANGE
$39.75 - $61.08
52 WEEK CHANGE
$12.77
DIVIDEND
$0.60
EX-DIVIDEND DATE
07/05/2024
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Giovanni Caforio
Region: US
Website: bms.com
Employees: 34,300
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: bms.com
Employees: 34,300
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
Recent news